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Prostate cancer (PCa) is the most common malignancy in elderly men. The progressive ageing of the world male population will
further increase the need for tailored assessment and treatment of PCa patients. The determinant role of androgens and sexual
hormones for PCa growth and progression has been established. However, several trials on androgens and PCa are recently focused
on urinary continence, quality of life, and sexual function, suggesting a new point of view on the whole endocrinological aspect
of PCa. During aging, metabolic syndrome, including diabetes, hypertension, dyslipidemia, and central obesity, can be associated
with a chronic, low-grade inflammation of the prostate and with changes in the sex steroid pathways.These factors may affect both
the carcinogenesis processes and treatment outcomes of PCa. Any treatment for PCa can have a long-lasting negative impact on
quality of life and sexual health, which should be assessed by validated self-reported questionnaires. In particular, sexual health,
urinary continence, and bowel function can be worsened after prostatectomy, radiotherapy, or hormone treatment, mostly in the
elderly population. In the present review we summarized the current knowledge on the role of hormones, metabolic features, and
primary treatments for PCa on the quality of life and sexual health of elderly Pca survivors.
1. Introduction
Prostate cancer (PCa) is the most common malignancy in
elderly men. Age is a relevant risk factor, with a proven
histological PCa being found in 60% of men by the age of 70
years and 80% by the age of 80 [1]. In fact, PCa is considered
a chronic disease, needing a long period for initiation,
development, and progression, through the development of
early and later precancerous modifications, such as high-
grade prostate intraepithelial neoplasia (HG-PIN), leading
to the development of a clinically relevant cancer [2, 3].
Therefore, PCa is frequent in old men, likely becoming the
prevalent cancer because of the ageing of population [4].
Although androgen receptor (AR) pathway is crucial for
prostate cancer growth and progression, evidence supporting
a favorable risk-benefit ratio of androgen deprivation therapy
(ADT) is currently limited to high-risk PCa or metastatic
disease [5, 6]. Furthermore, hypogonadism is common in
elderly men andmenwho have PCa: the symptoms of hypog-
onadism, such as depression, erectile dysfunction (ED), and
lower urinary tract symptoms, can impair a man’s quality of
life (QoL) [7].Therefore, androgens andARplay a critical role
in management of elderly men with PCa.
The current literature suggests an association between
metabolic syndrome (MetS) and PCa, although the evidence
for a causal relationship remains unknown [8]. In particular,
a recent review pointed out that men with MetS seem to
have more likely high-grade and advanced PCa: moreover,
they resulted in greater risk of progression and cancer
specific death, even if the overall analyses did not reveal any
association between MetS and the risk to develop the disease
[8]. Therefore, MetS should be assessed as a new domain in
basic and clinical research in elderly men with PCa.
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Figure 1: Schematic representation of the main pathways involved in development of castration-resistant prostate cancer (CRPC). ADT:
androgen-deprivation therapy, AR: androgen receptor. Modified from 43.
The primary goal of any definitive treatment of PCa is
the improvement of survival and QoL: although surgery,
radiotherapy, and hormone therapy can lead to long-term
survival, these treatments can cause lasting side effects [9].
Therefore, patients survival has to be considered in treatment
decision making, but patients’ quality of life must also be
considered before and after any treatment [10]. Moreover,
an accurate assessment of QoL in PCa patients must be
performed with validated, self-reported, and disease specific
instruments [11]. Therefore, there is a need for a tailored
approach in the management of PCa in the elderly men,
to avoid unnecessary intervention with permanent adverse
event [12].
The aim of present review is to summarize the current
knowledge on the role of androgens pathways, metabolic
factors, and primary treatments on the overall QoL and
sexual health of elderly PCa survivors.
2. Endocrinological Aspects of Prostate Cancer
2.1. The Role of Androgens and of Androgen Receptor (AR) in
Carcinogenesis and Progression of Prostate Cancer. Prostate
volume and function are age- and androgen-dependent
[13] and in hypogonadal subjects therapy with testosterone
restores the volume of the prostate to that of eugonadal
men [14]. Androgens and AR play a fundamental role in the
development of PCa which is androgen-dependent for its
growth, as demonstrated in the pioneering work of Huggins
and Hodges [15] who showed that castration causes complete
regression of the disease.
How actions of AR become tumorigenic and lead to
uncontrolled growth remains poorly understood. In a high
percentage of PCa, fusions between the androgen-dependent
gene TMPRSS2 and ETS transcription factors (such as ERG)
occur through chromosomal translocations [16], leading
to elevated expression of these oncogenic factors under
androgen control. However, whether TMPRSS2:ETS fusions
are sufficient to promote PCa is discussed [17, 18] and the
initial enthusiasm about such chromosomal aberrations has
been dampened by the controversial results of clinical studies
investigating their role in PCa progression [19].
Androgen deprivation therapy (ADT) represents a valu-
able treatment of metastatic PCa. However, ADT provides
palliation but not cure and most PCa regrow as castration-
resistant PCa (CRPCa) able to survive and grow in a milieu
virtually deprived of androgens. The detailed mechanisms of
whyADT ultimately fails and amore aggressive cancer recurs
remain unclear (Figure 1). In the past decade, based on in
vitro or in vivo evidence, several hypotheses involving the
AR have been generated to explain development of CRPCa,
such as AR mutations (found in about 20% of metastatic
specimens) or amplifications that confer the ability to bind
other steroids and even antiandrogens (acting as agonists),
changes in AR-coregulators interactions, and activation of
AR by growth factors or other signal pathways (reviewed
in [20]). In addition, recent work has highlighted the role
of intraprostatic androgen synthesis as the driving force of
recurrent disease (see below for further details).
Interestingly, low expression of mutated AR may drive
in vitro growth of CRPCa cell lines also by nongenomic
(rapid signalling) mechanisms [21]. However, more studies
are needed in order to better understand the role, if any, of
nongenomic AR signalling in PCa growth and progression.
These AR-involving hypotheses do not completely explain
why patients receiving ADT tend to have an earlier devel-
opment of more aggressive cancer. Alternative pathways of
growth and invasion may develop in PCa cells (Figure 1)
bypassing the necessity of androgens: among these, PTEN
inactivating mutation has been found in a high proportion
of PCa [22] leading to suppression of apoptotic pathways
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and consequent uncontrolled growth. Neuroendocrine dif-
ferentiation also plays an important role in development
of CRPCa [23]. In summary, development of CRPCa is a
very complex event, potentially involving both androgen-
regulated and androgen-alternative pathways (Figure 1). Such
a complexitymakes the development of therapeutic strategies
very difficult, and, as today, CRPCa is basically incurable.
Currently, research is mainly directed to understand the
role of these multiple pathways and their interregulation
with the aim of identifying potential therapeutical targets.
One hot topic of research is aimed at understating the role
of AR. In a recent survey of the literature concerning the
relationship between AR expression in PCa specimen and
disease prognosis, we have highlighted the conflicting results
reported so far [24]. These studies evidenced both the highly
variable expression of AR among different cancers and a dif-
ferent relation with prognosis. Most studies did not find any
association between AR expression and prognosis, including
a large one by Minner et al. [25], whereas some studies found
an association between high AR expression and better or
worse prognosis. Although such contrasting findings may
depend on several factors [24], one possible explanation may
be related to a different role of AR depending on its location
(stromaor epithelium) in the tumor. Recently, amouse cancer
model lacking the AR only in the prostatic epithelium and/or
stroma has been generated (ARKO-TRAMP) [26, 27]. These
mice paradoxically develop poorly differentiated PCa and,
most importantly, restoration of AR function in epithelial
basal cells leads to tumor suppression. Conversely, restora-
tion of AR in stromal cells stimulates cancer progression,
supporting a differential role of AR in PCa depending on
its location. Studies in mice models suggest that stromal
AR may promote prostate tumorigenesis via induction of
proinflammatory cytokines/chemokines expression [28].
These results substantiate in vitro studies showing that
enforced expression of AR inAR-negative PCa cells decreases
the metastatic/invasive potential of the cells [26, 29–35]. In
a recent paper evaluating the role of androgen signalling
in epithelial-mesenchimal transition, Zhu and Kyprianou
[36] demonstrated that overexpression of AR in PCa cell
lines suppresses androgen-induced epithelial-mesenchimal
transition, suggesting that downregulation of AR occurring
in androgen-deprived condition [37] may facilitate mes-
enchimal transition and promote metastasis [36]. There is
also evidence that inducing AR expression in PCa cells by
targetingmethylation of promoter increases differentiation of
carcinoma cells and suppresses self-renewal/proliferation of
stem cells and tumorigenesis [38].
Clinical data supporting a differentiating role of AR
in PCa and, as such, limiting invasiveness have been also
published. Following androgen ablation metastatic PCa is
promoted in vitro [39] and there is clinical evidence that
intermittent ADT benefits patients in PCa progression [40].
In addition, patients with CRPCa displaying amplification of
AR gene survive longer than patients without amplification
[41]. Results of long-term survival in the PCa prevention trial
with the 5 alpha-reductase inhibitor finasteride demonstrated
that, although the risk of developing PC is decreased, the
Gleason score of developing cancers is significantly higher
in the finasteride group and, overall, no difference in life
expectancy between the treated and placebo group was
observed [42]. Finally, there is evidence in the literature
that, in some instances, CRPCa may benefit from androgen-
replacement therapies [43–45]. Overall, these studies suggest
that AR may have both negative and positive roles in PCa
progression by regulating cell growth and invasion ability
[46, 47].
In such a complex scenario, it is clear that more studies
are needed to define the role of AR in the different PCa
compartments. In addition, investigations should be aimed
at evaluating the different AR variants present in the tumors.
Indeed a recent study [48], performed in a small series
of CRPCa bone metastases (𝑛 = 30), demonstrated that
expression of AR variants lacking the ligand binding domain
was associatedwith poor prognosis and shorter survival rates.
If these results will be confirmed in a larger series of subjects,
they can open new therapeutic perspectives to target other
portions of AR. Of interest, an AR antagonist, EPI-001, able
to bind the N-terminal domain of AR, has been recently
developed [49, 50]. This antagonist has been found to reduce
the growth of CRPCa xenografts [51].
2.2. Prostate Cancer in Hypogonadal Men. Although a
causative role for circulating androgens on PCa has been
envisaged since the Huggins and Hodges studies, data clearly
showed that such a link is at best unproved. In ameta-analysis
of 18 prospective studies, including almost 4000 men with
incident PCa and 6500 control subjects, no associations were
found between the risk of PCa and serum concentrations of
Testosterone (T), calculated FT, DHT, and other androgens
[52]. Furthermore, some authors have documented that low
serum T is associated with more aggressive, ADT-resistant
tumors suggesting that low levels of androgens create a selec-
tive pressure for PCa cells leading to androgen-independence
([53, 54]; for review see [55, 56]).
In line with these data, the pooled odds ratio for
Testosterone Replacement Therapy (TRT) derived from 19
randomized clinical trials was 1.09 (0.48–2.49, 95% CI) for
PC and 1.19 (0.67–2.09, 95% CI) for PSA > 4 ng/dL or 1.5%
increase during study (for review see [55, 56]). Based on
critical analysis of clinical trials and on the aforementioned
experimental data on PCa cell lines, so far 11 investigators
evaluated the effect of TRT even in PCa patients, with the
aim of inducing differentiation in the tumor [55, 56]. Overall
these studies included 279 subjects previously treated with
radical prostatectomy or radiotherapy. In the vast major-
ity of patients no association with progression or clinical
recurrence was reported. Despite this evidence, it should be
recognized that the number of reported cases is still small
and heterogeneous. In the absence of randomized controlled
trials (RCT), the concept of using TRT for PCa survivors
is debatable. Accordingly, current recommendations suggest
limiting TRT to symptomatic hypogonadal men successfully
treated for PCa, after a prudent interval, although the length
of that interval is not specified [57].
2.3. Intraprostatic Synthesis of Steroids: Role in PCa Progres-
sion. As mentioned above, intraprostatic androgen synthesis
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may support PCa cell growth even in the virtual absence
of androgens contributing to development of CRPCa [13].
There is evidence that androgen levels may remain elevated
in the prostate during ADT [58, 59]. Moreover, androgens
have been found in locally recurrent CRPCa [60] and in
distant metastasis [61]. These studies suggest that the PCa
may acquire the capability to synthesize androgens although
a direct proof can be only obtained by demonstrating the
occurrence of steroidogenic machinery in the cells. Results
of the latter experiments are contrasting [62, 63]. In partic-
ular, in a recent study [62], expression of the steroidogenic
enzymes CYP17A1 and HSD3B1, essential for androgen syn-
thesis, has been detected at low levels only in 19 of the 88
tumor samples leading to the conclusion that intratumoral
steroid biosynthesis has a limited contribution. However, the
elevated expression of 5 alpha-reductase found in CRPCa
samples [63] suggests that de novo steroidogenesis may occur
bypassing the requirement of T by 5 alpha-reduction of
adrenal precursor steroids [13]. Targeting androgen synthesis
in CRPC with abiraterone acetate, a potent inhibitor of
CYP17, resulted to be safe and well tolerated, leading to a
reduction of the risk of death and increased median survival
of some months compared to placebo [64]. At present ongo-
ing investigations are evaluating the efficiency of abiraterone
acetate (in combination with other treatments) in the early
stages of PC. Efforts are currently directed to understand the
mechanisms of resistance to abiraterone acetate and how to
prevent it.
2.4. Modifications of Sex Hormone after Radical Treatment
for Prostate Cancer. Several studies have analyzed the mod-
ifications in the levels of T and gonadotropins following
radical treatment, producing controversial results [65–68].
In particular, in 55 males treated with radical prostatectomy
(RP), a remarkable increase in T, luteinizing hormone (LH),
and follicle-stimulating hormone (FSH) has been reported 1
year after RP [69].These data were confirmed by Olsson et al.
[66]. In a group of 49 men, LH and FSH were increased by 71
and 63%, respectively, 12months after RPwithout any evident
changes in T, suggesting that the hypothalamic pituitary axis
was inhibited in patients with PCa and that this inhibition has
been removed following RP [69].
Recently, we enrolled 100 men affected by PCa in a single
center prospective study, with the aim to evaluate the changes
in the serum levels of T, LH, and FSH within the first 3
months after RP for clinically localized PCa and to analyze
the correlation between LH and T at various follow-up times
[67]. As expected, we found a remarkable positive correlation
between T and LH before surgery (𝑟 = 0.370; 𝑃 < 0.0001),
but not 1 month after RP (𝑟 = 0.109; 𝑃 = 0.303). Three
months after prostatectomy, the correlation between T and
LH was restored (𝑟 = 0.273; 𝑃 = 0.054). Therefore, our data
demonstrated that RP can induce an early significant decline
in the T levels and a compensatory increase in LH and FSH
levels. These data have a critical relevance, suggesting that
hormone modifications could have an important role in the
loss and the subsequent recovery of both urinary continence
and potency [70]. Three months after RP, the full recovery of
T levels, with persistent high levels of gonadotropins, seems
to delineate the features of compensated hypergonadotropic
hypogonadism.
To confirm these data and to analyze the influence of T
on sexual activity and urinary continence in men with PCa,
we consecutively enrolled 257 patients treated with RP in our
center [71]. As expected both age and BMI have a negative
impact on preoperative T levels. Moreover, in men with
normal T, urinary continence was significantly correlated
with sexual function and sexual bother (𝑟 = 0.2544: 𝑃 = 0.01
and 𝑟 = 0.2512: 𝑃 = 0.01), whereas this correlation was lost
in hypogonadal men.
3. Metabolic Syndrome and Prostate Cancer in
Elderly Men
Metabolic syndrome describes the combination or clustering
of several metabolic abnormalities including central obesity,
dyslipidemia, hypertension, insulin resistance with com-
pensatory hyperinsulinemia, and glucose intolerance [72–
74]. Recently, epidemiological, histopathological, molecular
pathological, and clinical studies have provided emerging
evidence of a possible role ofMetS and its components in PCa
development and progression [74, 75].
Although the only well-established risk factors associ-
ated with PCa are age, race, and family history, the large
geographical variations in PCa risk suggest that lifestyle and
environmental factors may also contribute to its etiology.
The possibility to prevent and treat MetS and its components
led to novel therapeutic approaches that have been proposed
as a new frontier in the prevention and treatment of PCa
[74, 76, 77].
3.1. Definition, Epidemiology, and Pathophysiology. MetS is a
constellation of physiological and biochemical abnormalities
characterized by diabetes or high fasting glucose, central
obesity, abnormal cholesterol and triglyceride levels, and
hypertension [78]. Currently, the two most widely used
definitions are those proposed by the National Cholesterol
Educational Program Adult Treatment Panel III (NCEP:ATP
III) and by the InternationalDiabetes Federation (IDF) focus-
ing on abdominal obesity measured by waist circumference.
In contrast, the World Health Organization (WHO) and the
European Group for the study on Insulin Resistance (EGIR)
definitions are principally focused on IR [73, 74].
Prevalence of MetS increases linearly from the age of 20
until age of 50, when it plateaus and affects more than 40% of
the population in the United States and nearly 30% in Europe
[79, 80]. Similar to western countries, the prevalence of MetS
is rapidly increasing in developing countries, ranging from
9.8% in males from urban north India, to 16.3% in Morocco,
to 25.4% in urban Brazil, to 33.5% in South Africa, and to
33.7% in Iran [74, 78, 79]. People with MetS are estimated
to have twice the risk of developing cardiovascular disease
compared to healthy individuals and a fivefold increased risk
of type-2 diabetes. MetS has been recently linked to a number
of urological diseases including PCa [72, 75]. Although IR
and obesity are considered at the core of the pathophysiology
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of MetS, a number of other factors can also be involved in its
pathogenesis and potential interactions [73, 74].
In most cases MetS develops as a result of poor eating
habits and/or sedentary lifestyles which are associated with
IR and obesity. IR occurs when there is a decrease in
the responsiveness of peripheral tissues (skeletal muscle,
fat, and liver) to the effect of insulin with a concomitant
hyperinsulinemia [80]. Hyperinsulinemia is also responsible
for stimulating Insulin Growth Factor-1 (IGF) production in
the liver. IGF-1 is a potent mitogenic factor and apoptosis
inhibitor which has been linked with PCa risk [81].
Central obesity is also considered an early step in the
development and progression ofMetS. Visceral adipose tissue
secretes various bioactive substances known as adipocy-
tokines which can induce IR and have proinflammatory
and proatherogenic effects (Figure 2). Cytokines includ-
ing resistin, leptin, tumor necrosis factor alpha (TNF-𝛼),
interleukin-6 (IL-6), C-reactive protein (PCR), fibrinogen,
and plasminogen activator inhibitor (PAI-1) are normally
increased in obese patients and in patients with DMT2.
On the contrary, adiponectin, is lower in individuals with
visceral fat accumulation. Adiponectin stimulates glucose
metabolism and fatty acid oxidation in the muscle, enhances
insulin sensitivity in the liver, increases free fatty acid
oxidation, reduces hepatic glucose output, and inhibits
monocyte adhesion andmacrophage transformation to foam
cells within the vascular wall [80, 82]. Visceral adiposity
may also contribute to hypogonadism, frequently associated
with MetS in men, through increased aromatase activity.
Its increased activity in obese patients raises estradiol lev-
els, which results in feedback inhibition at the level of
the hypothalamus/pituitary to lower T leading to hypogo-
nadrotropic hypogonadism. Elevated estrogen levels lead to a
further increase in visceral adipose deposition creating a self-
sustained loop [74, 80, 82].
MetS has also been associated with a state of chronic,
low-grade inflammation. Several studies showed that patients
with MetS were more likely than those without to have
elevated levels of amarker of inflammation such as C-reactive
protein (CRP) as well as proinflammatory cytokines such as
TNF-𝛼, IL-8, IL-6, and IL-1𝛽 [83, 84].
3.2. Relationship betweenMetS and PCa. MetS has frequently
been associated in human and animal models with carcino-
genesis (see Table 1) [85]. It has recently been suggested that
evaluatingMetS as a single conditionmay be an inappropriate
approach to investigating PCa risk. Specifically, combining
all the multiple components of the syndrome into a single
variable may confound or obscure the independent effects
and interactions of these metabolic components on PCa risk
[86]. Each of the primary components of the MetS have
been individually observed to be directly associated with
PCa risk. DMT2 has been associated with a reduction in
PCa risk, probably in relation to the changing action of
insulin over the course of diabetes progression [86, 87].
The presence of hypertension may increase PCa risk, in
part through increased sympathetic nervous system activity,
which can result in androgen-mediated stimulation of PCa
cell growth [86]. Men with lower plasma cholesterol were
less likely to develop high-grade PCa than men with higher
concentrations; this effect might be mediated by several
pathways including androgen metabolism and intracellular
cholesterol-mediated signaling [88, 89]. Most recent large
studies suggest that obesity is associated with a decreased risk
of low-grade disease, but an increased risk of high-grade and
advanced PCa [74].
Moreover, obesity was associated with an increased risk
of intraoperative and perioperative complications and with
a worse functional outcome, in men treated with RP [90].
In particular, obese men are at threefold greater risk of
intraoperative complications and blood transfusions than
not-obese men (adjusted odds ratio (OR) = 3.116, 𝑃 < 0.001,
and OR = 2.763, 𝑃 < 0.050, resp.). Furthermore, the risk
of needing at least two pads per day is two and a half times
greater in men with a waist circumference of at least 102 cm
than in those with a WC below 102 cm (adjusted OR = 2.435,
𝑃 = 0.007).
In conclusion, further basic and clinical studies are
needed to evaluate this association by investigating all these
metabolic conditions as a whole and to better evaluate the
role the MetS and its mediators with the development and
progression of PCa.
4. Measurement of Quality of Life and Sexual
Health in Men with Prostate Cancer
Any treatment of PCa can affect urinary and sexual activity,
psychosocial function, and overall wellbeing. Several vali-
dated questionnaires have been used to asses QoL after RP.
An effective evaluation should consider at least 3 categories of
QoL: (1) the organ specific function (urinary and sexual); (2)
the physical status and the mental health in the patients with
any type of cancer; (3) the general health status.The following
validated questionnaires are the most accurate to assess the
overall health and quality of life for men with PCa.
4.1. UCLA-PCI. The University of California-Los Angeles
Prostate Cancer Index (UCLA-PCI) is very accurate to eval-
uate all aspects related to QoL before and after any treatment
for PCA. This questionnaire investigates urinary, bowel and
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sexual function (UF, BF, and SF), and bowel and sexual bother
(UB, BB, and SB) and has been designed either for urologists
or radiotherapists [97, 98]. The majority of questions were
assigned a score from 0 to 100 (0 = worse health; 100 = better
health).
4.2. European Organisation for Research and Treatment of
Cancer (Cancer Generic): EORTC QLQ-C-30. This validated
questionnaire, designed to evaluate the QoL in men affected
by or treated for any cancer, is a 30-item questionnaire
composed of multi-item scales and single items that reflect
the multidimensionality of the quality-of-life construct [99].
It incorporates five functional scales (physical, role, cognitive,
emotional, and social), three symptom scales (fatigue, pain,
and nausea/vomiting), and a global health and QoL scale.
4.3. Short Form-12 (SF-12). The SF-12 is the short version of
the SF-36 questionnaire [100].Through 12 questions, it allows
investigating, instead of the 8 original scales, only two indices:
the Physical Component Summary (PCS) and the Mental
Component Summary (MCS). The strengths of this form are
the brevity and relative ease of use from both patients and
physicians. For every question there are from 3 to 5 options.
4.4. International Index of Erectile Function (IIEF). The
IIEF questionnaire is a validated multidimensional self-
administered questionnaire used to assess the erectile func-
tion and the response to treatment in clinical trials. A score
of 0–5 is awarded to each question that evaluates 4 domains
of sexual health: sexual desire, erectile function, orgasmic
function, and intercourse satisfaction [101]. Recently, a short
form (IIEF-5), based on 5 questions instead of the original 15
questions, has been used.
5. Impact of Primary Treatment for Pca on
QoL and Sexual Health
Currently, more than half of all PCa are clinically localized at
the diagnosis, with a 5-year biochemical disease-free survival
above 85% [102]. Treatment options for clinically localized
PCa include watchful waiting, radical prostatectomy, radical
external beam radiation, and hormone treatment. Neverthe-
less, while active surveillance may have a minimal impact on
either QoL or sexual health, more invasive therapies can lead
to clinically significant and lasting side effects [103].
In particular, erectile dysfunction and urinary inconti-
nence after RP, bowel, urinary, and sexual complications after
radiotherapy or sexual and continence andmoodbothersome
after hormone treatment can have a negative impact on all
the aspects of QoL, including vitality, social and physical, and
emotional limitations.
5.1. Primary Treatment in the Elderly Men. The appropriate
management of the older men can be a challenge: elderly
men aremore likely to be diagnosedwith higher-grade cancer
and the presence of comorbidity and functional decline can
impact on treatment tolerance and side effects [104, 105].
Therefore, RT and/or ADT aremore commonly used because
they are less invasive and do not carry the risk of surgery and
anesthesia.
PC is often diagnosed as a result of routine screening in
asymptomatic patients, so the development of late treatment
sequelae may be particularly alarming [106], also considering
the improvement of life expectancy in elderly population
(over 17 years at 65 years old) [107].
QoL is a key criterion in the choice of treatment, particu-
larly for early PC or elderly patients, but it is difficult to assess
despite the availability of validated questionnaires [108–112].
Late QoL impact is well documented in the literature, but
most of the longest QoL studies did not include pretreatment
evaluation [113, 114] or collected it retrospectively [115–117].
Generally, recent cohort prospective studies of patients
show a different pattern of late sequelae: an increased
prevalence of urinary incontinence after prostatectomy, of
urinary irritative obstructive symptoms after brachytherapy,
of bowel side effects after EBRT, whereas sexual dysfunction
as common late event after all these treatment including ADT
[110, 111, 118–120].
In particular, erectile dysfunction (ED) is a critical point
related to QoL in men treated for PCa and it is strongly
associated with depression and significant distress [119, 121,
122]. ED in these patients is the result of several factors:
anatomic changes after surgery or radiotherapy, not only
hormonal therapy but also psychological and social factors
and finally specific comorbidities that often occur in elderly
men (metabolic syndrome, diabetes, obesity, osteoporosis,
reduced muscle mass, and strength) [123–126].
5.2. Radical Prostatectomy. The major concerns for patients
undergoing RP are postprostatectomy incontinence (PPI)
and ED. Both QoL and sexual health after RP are strongly
dependent on patient age, aging, tumor characteristics, and
disease progression [112]. While slight urinary of sexual
dysfunction can lead to important bother in younger men,
remarkable symptoms can generate minimal bother in the
elderly. QoL and sexual health can progressively change
owing to anatomical modifications, treatment for PCa, or
the natural aging [127]. Therefore, age at time of treatment
and perspectives in both sexual and general health have the
same clinical relevance of tumor features [128]. Finally, tumor
progression or recurrence after RP can generate anxiety and
fear that can further worsen QoL and sexual health [129]. In
a retrospective, cross-sectional study, enrolling 595 men with
PCa treated with radical treatment as primary therapy, we
demonstrated that pretreatment tumor characteristics (clini-
cal stage, bioptical Gleason score, and total PSA), treatment
timing (age at time of treatment, follow-up duration after
treatment, and age at time of follow-up), and posttreatment
outcomes (biochemical recurrence and hormonal status) had
a remarkable impact on QoL.
One of the leading determinants of QoL and sexual
health after RP is the surgical approach: a more conservative
procedure, sparing neurovascular bundles, bladder neck, and
proximal urethra can strongly increase the chance of better
functional outcomes [130, 131]. The decision for the surgical
approach is usually a compromise between patient’s desire to
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Figure 3: Comparison of function and bother in long-term disease-free survivors after nerve sparing RP without hormone treatment: UF:
urinary function; UB: urinary bother; SF: sexual function; SB: sexual bother; RP: radical prostatectomy (adapted from [70]).
preserve sexual activity and the eligibility to a conservative
surgery based on tumor characteristics (PSA, Clinical stage,
bioptical Gleason Score). In a prospective survey on 2,408
PCa patients treated with RP, we demonstrated that at least
737 men (30.6%) were interested in preservation of sexual
activity, but not eligible for a nerve-sparing procedure, based
on their high-risk PCa features [132]. For 372 (50.5%) of these
patients a nerve sparing approach (monolateral or bilateral)
was chosen: in these highly selected cases, surgeons’ strategy
was performed in accordance with patients’ desire, without
compromising surgical margin status.
The complete recovery of urinary continence after RP
is mandatory to preserve general health and to maximize
the outcomes of sexual rehabilitation: after catheter removal,
most patients reported some level of urinary incontinence
[132]. In a multicenter prospective study, we enrolled 1972
men with full continence preoperatively and complete post-
operative data: 1 month after RP, 644 (32.7%) were fully
continent, 810 (41.1%)were using 0-1 pad/day, and 518 (26.3%)
>1 pad/day. Age and nerve sparing were not significant
predictors of continence recovery after RP, while preoperative
erectile function allowed predicting PPI: the integrity of
pelvic vasculature and nerves prior to RP was determinant
to avoid of early PPI.
ED and urinary continence can improve even beyond
more than 1 year postoperatively, with an average time to
sexual and urinary recovery of >6 months [133]. More-
over, Phosphodiesterase type 5 inhibitors (PDE5-I), either
in nightly or on-demand dosing, are the gold standard to
recover sexual function after nerve-sparing prostatectomy
[134]. In a multicenter RCTwe have randomizedmen treated
with nerve sparing prostatectomy for localized PCa into 3
groups: (1) PDE5-Is on demand; (2) PDE5-Is once a day;
(3) placebo [135]. PDE5-IS improved continence recovery
compared with placebo (Improvement of Urinary Function
at 3, 6, and 9months after PDE5-Is once a day versus placebo:
𝑃 = 0.042,𝑃 = 0.044, and𝑃 = 0.039, resp.): the positive effect
of PDE5-I on continence recovery, even in the absence of the
prostatic gland, suggested a direct activity of PD5-Is on lower
urinary tract by a pathway not including prostate. Therefore,
the long-term use of PDE5-Is after RP can strongly influence
the general QoL, the urinary function, and the sexual health.
During the natural aging process in disease-free survivors
after RP, both urinary and sexual symptoms and bother can
be strongly modified, due to hormonal modification and
both vascular and nerve impairment. Moreover, after long-
term disease-free follow-up, several men reconsider their
QoL status [136]. In two tertiary referral center for PCa we
recruited 367 men treated with RP (for clinically localized
PCa), without biochemical failure (PSA ≤ 0.2 ng/mL) at
the follow-up ≥5 years, with the aim to evaluate long-term
general QoL and sexual health in elderly PCa survivors [70].
Older men presented worse urinary continence regardless of
age at time of surgery or follow-up duration. Moreover, after
more than 8 years after nerve sparing RP without hormone
treatment, patients reported substantial sexual dysfunction,
but, interestingly, they wereminimally sexually bothered (see
Figure 3). Our data confirmed that slight urinary inconti-
nence is poorly tolerated even after several years of complete
cancer control, while sexual dysfunction is better tolerated,
in the daily life of long-term disease-free survivors, perhaps
because patients consider ED as a part of their natural aging.
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5.3. Radiotherapy. Current indications for external-beam
radiotherapy (EBRT) in PC include primary treatment (in
localized intracapsular tumors or combined with ADT in
locally advanced and high-risk PC), adjuvant treatment
in patient with adverse pathologic features, (extracapsular
extension, positive surgical margins), and salvage radiother-
apy (after radical prostatectomy) [137].
However, over recent years, radiotherapy (RT) has seen
major advances such as the introduction of intensity-
modulated radiation therapy (IMRT) and image-guided RT
(IGRT) [138, 139]. The higher radiation doses that can be
delivered to the prostate by these new techniques, whilst
sparing surrounding organs, have improved progression-free
survival and reduced acute and late toxicities [140, 141].
Several studies investigated this aspect of QoL [119] with a
short (1–3 years) or intermediate (4-5 years) follow-up, while
longer-term outcomes remain largely unknown. Regarding
age of patients, some studies have found equal rates of both
acute and late side effects in all age groups [142, 143] while
others have found older age to be associated with faster
onset and more frequent side effects [71]. A prospective
trial evaluating patients more than one year following EBRT
treatments with final dose of 70–72Gy found that older age
and diabetes were predictive of both preexisting ED and post-
EBRT acquired ED [144].
Sanda et al. concluded a substantial decline from baseline
of sexual function at 2 years after surgery, but only a
moderate decline after EBRT or brachytherapy. Recovery of
sexual function was worse in patients treated with androgen
suppression combined with radiotherapy, in older patients,
obese patients, and patients with a larger prostate size and a
high pretreatment PSA. The patient’s QoL concerning sexual
function was also significantly related to satisfaction in the
partner [111].
Pardo et al., in a Spanish study, had similar results after
a follow-up of 3 years in patients treated by surgery or EBRT
or brachytherapy [145], as well as Rice et al. in a USA study:
the authors concluded that EBRT had no significant impact
on sexual function at 12 months and may be offered to
older patients with minimal QoL impact [146]. As reported
in the studies of Potosky et al. [115], the Prostate Cancer
Outcomes Study (PCOS), and the one of Miller et al. [113],
the patients treated by surgery had an improvement in their
sexual function at 2 years after diagnosis, whereas the patients
treated by EBRT had slight declines: a possible explanation of
this result is the older age of the group of patients treated by
radiotherapy. Instead in the Litwin’s et al. report long-term
sexual function scores were better among surgical patients,
but return to baseline was more rapid in patients treated by
EBRT [147].
In their report of a long-term follow-up, Resnick et al.
[148] described that, although patients undergoing RP were
more likely to have ED at 2–5 years, at 15 years the prevalence
of ED is very common, affecting 87% of men treated by
surgery and 93.9% of men treated by EBRT: it is matter of
debate if this decline is due to late sequelae of oncologic
treatments, to normal aging process, or to a combination of
these factors. Van der Wielen et al. studied the correlation
between ED and dose to penile bulb in patients treated with
doses of 68–78Gy: but there was no relation found [149].
Mangar et al. demonstrated that a dose received by 90% of the
penile bulb (D90) >50Gy was significantly associated with
ED (𝑃 = 0.006) [150], results comparable to the outcomes of
the study of Wernicke et al. [151].
The RadiationTherapyOncology Group 9406 trial exam-
ined 158 men with a regular erectile function at baseline and
found a greater risk of impotence with a penile mean dose
>52.5Gy (𝑃 = 0.039) [152]. So these data are suggestive
for a correlation between dose to penile bulb and ED, but
more prospective studies are indispensable for predicting
preservation of sexual function.
Regarding alternative fractionations, the low 𝛼/𝛽 ratio of
PC causes the high sensitivity of these cells to higher doses for
fraction than other tumors [153, 154], even if it is well known
that hypofractionated treatments can result in increased rate
of late toxicity. In a Canadian prospective study, at 39 months
of follow-up, moderate and severe distress related to urinary
and bowel symptoms was minimal (3% and 5% of patients,
resp.), and the rate of sexual dysfunction was in line with the
studies with conventional fractionations [155].
Finally, the few studies available concerning QoL after
dose-escalated radiotherapy (thanks to advances in radio-
therapy techniques) suggest an increased radiation dose does
not result in decline of QoL [156–159].
5.4. Androgen Deprivation Therapy (ADT). Approximately
50% of men with PCa receive ADT at some time after
diagnosis, and most will take it for at least 2 to 3 years
[160, 161]. Currently, luteinizing hormone-releasing hormone
(LHRH) agonists are the most frequently used agents for
ADT. However, other agents including high-dose estrogen,
high-dose ketoconazole, abiraterone, and LHRH antagonists
can also be used to achieve a castrate level of T. Single-agent
antiandrogen therapy is also used as a form of ADT, but it is
more likely to reach lower serum T levels [162].
ADTpresents several symptoms of “castration syndrome”
as side effects, based on low serum T concentration. The
symptoms include loss of libido and sexual interest, erectile
dysfunction, general fatigue, decreased intellectual ability,
depression, loss of muscle strength, increased abdominal fat
mass, and loss of vigor [163]. Several cross-sectional studies
have described the effect of ADT on self-reported physical
function; these studies consistently found that ADT treated
men reported decreased physical function in comparison to
nontreated [164, 165].
Regarding the side effects of hormonal therapy, in a
Canadian retrospective study of Joly et al. [166, 167] patients
treated with ADT for at least 3 months for localized PCa
both as adjuvant therapy and as biochemical relapse were
enrolled. Tests were administered to assess the: patients
had significantly poorer scores than controls, especially for
urinary disorders and sexuality (𝑃 < 0.01). The urinary
and sexual symptoms may be primarily due to the prior
local treatment. ADT contributed to deterioration in sexual
functions, but this study was not designed to address this
question; of the patients, 90% reported sexual problem, in
agreementwith results of other studies [168].However elderly
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patients often report that urinary symptoms have a greater
impact than sexual functions on global QoL [166, 169].
In an Australian longitudinal study the authors inves-
tigated the change to QoL and T level in men starting
an intermittent maximal androgen blockade program. Two
hundred and fifty men were recruited in this multicentre
study: T suppression leads to a significant reduction in
global QoL and deterioration in most function as sexual
function. Complete loss of libido increased from 37.2% before
treatment to 72.2% after hormonal deprivation. Complete
sexual inactivity increased from 54.3% to 86.9%. Following
treatment cessation, T recovery was gradual andmedian time
to eugonadal levels of the hormone was 9.3 months with an
improvement in emotional function, sexual function, fatigue,
sleep, and hot flushes [170].
In the American study of Lubeck, QoL of 1178 newly
diagnosed patients was examined (mean age at diagnosis
was 73 years) which were enrolled in the Cancer of the
Prostate Strategic Urologic Research Endeavor Database.
General and disease specific QoL outcomes were measured
with tests at study entry and quarterly thereafter. Patients
were randomized in 3 groups: ADT, surveillance, radical
prostatectomy, or EBRT.Men receiving ADT reported poorer
urinary and sexual function and a higher rate of urinary and
sexual symptoms than patients selecting surveillance. ADT
and surveillance QoL scores remained low in the year after
treatment, whereas men treated by RP showed improvement
in these scales [167].
In the Australian phase 3 trial of Denham, all patients
were given six months of leuprorelin, and radiotherapy
to the prostate and seminal vesicles after 5 months from
randomisation. After leuprorelin, patients were given either
no further treatment or an additional 12 months of leuprore-
lin. In addition to androgen suppression, men who were
randomly allocated to the two bisphosphonate groups were
given zoledronic acid for 18 months. In this study, 18 months
of androgen suppression worsened the adverse changes in
the “patients-reported-outcome” score caused by 6 months
of androgen suppression and radiotherapy. However, these
increases were restricted to only sexual activity, hormone
treatment related symptoms, fatigue, and financial problems
at 18 months after randomization. The increases were also
restricted in time [171].
Mature survival data frommenwith previously untreated,
locally-advanced disease reveal that bicalutamide monother-
apy provides survival benefits that do not differ significantly
from castration, while offering important advantages with
respect to the maintenance of physical capacity and sexual
interest [172]. Also the study of Stav confirms that sexual
interest appears to be better preservedwith bicalutamide than
with castration [173].
In the two largest phase III studies comparing bicalu-
tamide 150mg/die monotherapy with castration (orchiec-
tomyor the LH-RHagonist goserelin acetate) in 1453 patients,
the combined analysis at 12months showed that bicalutamide
was associated with a significant advantage for sexual interest
compared with castration (𝑃 = 0.029), although a decrease
was recorded in both groups [174].
6. Conclusions
In conclusion, the present review underlines the double role
of androgens and the androgen receptor in the development
and proliferation of PCa as well as in maintaining a correct
functional state of the prostate of elderly men. Evidence in
the literature suggests that maintaining a correct function of
the androgen receptor may limit PCa progression by keeping
a more differentiate state of the cells. Althoughmore RCT are
needed to better define the risk/benefit of androgen therapy
in elderly men previously cured for PCa, current evidence
indicates that treatment with androgens of hypogonadal men
with previous PCa may be safe and may ameliorate both
sexual health and QoL.
There are several lines of evidence regarding the emerging
role of MetS and its components in PCa development and
progression. Moreover, MetS can be associated with a state
of chronic, low-grade inflammation, in particular in elderly
men. We have summarized the evidence about the involve-
ment ofMetS in the pathogenesis of PCa, particularly of high-
grade disease and we suggested that MetS should be assessed
as a new domain in basic and clinical research in elderly men
with PCa. In particular, all the components of MetS should
be adequately assessed either before or after any treatment of
PCa.
It is mandatory to use validated questionnaire to provide
adequate details to patients not only regarding urinary and
bowel symptoms, but also regarding their sexual function
in order to avoid anxiety in patients and their families, to
provide adequate medical and psychological counseling, and
to analyze the progressivemodifications during the follow-up
of PCa survivors.
The adverse effects of surgery, radiotherapy, or androgen
deprivation may be more pronounced in the elderly pop-
ulation, especially those with lower functional status and
increased comorbidities, in particular regarding their sexual
health. Therefore it is important to consider the specific
benefits and risks for each treatmentmodality as they apply to
the elderly because of the greater risk in both short- and long-
term postoperative complications and mortality following
any radical treatment.
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